{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T20:29:03Z","timestamp":1768076943119,"version":"3.49.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","brachyjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brachytherapy"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.brachy.2024.12.005","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T09:06:52Z","timestamp":1737709612000},"page":"318-327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["HDR brachytherapy combined with external beam radiotherapy for unfavorable localized prostate cancer: A single center experience from inception to standard of care"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8691-517X","authenticated-orcid":false,"given":"Ka-Kit David","family":"Yeung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0711-3318","authenticated-orcid":false,"given":"Juanita","family":"Crook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7323-4701","authenticated-orcid":false,"given":"Gregory","family":"Arbour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7676-941X","authenticated-orcid":false,"given":"Cynthia","family":"Araujo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4740-0111","authenticated-orcid":false,"given":"Deidre","family":"Batchelar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1428-2080","authenticated-orcid":false,"given":"David","family":"Petrik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracey","family":"Rose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francois","family":"Bachand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.brachy.2024.12.005_bib0001","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/JU.0000000000002854","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.brachy.2024.12.005_bib0002","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(14)70040-3","article-title":"Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial","volume":"15","author":"Dearnaley","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.brachy.2024.12.005_bib0003","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/jama.294.10.1233","article-title":"Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial","volume":"294","author":"Zietman","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.brachy.2024.12.005_bib0004","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1200\/JCO.2005.05.2530","article-title":"Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 gy of radiotherapy with 78 gy","volume":"24","author":"Peeters","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.brachy.2024.12.005_bib0005","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2004.10.014","article-title":"Long-term outcome of high dose rate brachytherapy in radiotherapy of localised prostate cancer","volume":"74","author":"Astrom","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2024.12.005_bib0006","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijrobp.2007.06.054","article-title":"Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer","volume":"70","author":"Kuban","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2024.12.005_bib0007","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ijrobp.2007.11.066","article-title":"Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes","volume":"71","author":"Zelefsky","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2024.12.005_bib0008","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ijrobp.2007.09.020","article-title":"Effect of increasing radiation doses on local and distant failures in patients with localized prostate cancer","volume":"71","author":"Kupelian","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2024.12.005_bib0009","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2024.12.005_bib0010","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/S0167-8140(21)08948-9","article-title":"70: after ASCENDE-RT: outcomes of androgen deprivation, external beam radiation and LDR brachytherapy boost for high-tier intermediate and high risk prostate cancer treated at BC cancer Kelowna","volume":"163","author":"Zheng","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2024.12.005_bib0011","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.radonc.2020.09.047","article-title":"Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: mature 12-year results","volume":"154","author":"Hoskin","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2024.12.005_bib0012","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0360-3016(01)01607-8","article-title":"Is alpha\/beta for prostate tumors really low?","volume":"50","author":"Fowler","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2024.12.005_bib0013","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0360-3016(01)02664-5","article-title":"Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha\/beta ratio), similar to late-responding normal tissue","volume":"52","author":"Brenner","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2024.12.005_bib0014","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/jjco\/hyq118","article-title":"Swelling of the prostate gland by permanent brachytherapy may affect seed migration","volume":"40","author":"Kono","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.brachy.2024.12.005_bib0015","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s13014-015-0532-3","article-title":"Seed migration after transperineal interstitial prostate brachytherapy by using loose seeds: Japanese prostate cancer outcome study of permanent iodine-125 seed implantation (J-POPS) multi-institutional cohort study","volume":"10","author":"Nakano","year":"2015","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.brachy.2024.12.005_bib0016","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1118\/1.4712227","article-title":"Investigating the dosimetric and tumor control consequences of prostate seed loss and migration","volume":"39","author":"Knaup","year":"2012","journal-title":"Med Phys"},{"key":"10.1016\/j.brachy.2024.12.005_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1120\/jacmp.v8i4.2415","article-title":"Measurement of craniocaudal catheter displacement between fractions in computed tomography-based high dose rate brachytherapy of prostate cancer","volume":"8","author":"Kim","year":"2007","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.brachy.2024.12.005_bib0018","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.brachy.2009.04.006","article-title":"Needle applicator displacement during high-dose-rate interstitial brachytherapy for prostate cancer","volume":"9","author":"Yoshida","year":"2010","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2024.12.005_bib0019","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.radonc.2009.08.033","article-title":"Comparison of three radiotherapy modalities on biochemical control and overall survival for the treatment of prostate cancer: a systematic review","volume":"93","author":"Pieters","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2024.12.005_bib0020","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.21873\/anticanres.15030","article-title":"Comparison of physician-recorded toxicities and patient-reported outcomes of five different radiotherapy methods for prostate cancer","volume":"41","author":"Ito","year":"2021","journal-title":"Anticancer Res"},{"key":"10.1016\/j.brachy.2024.12.005_bib0021","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.brachy.2021.07.005","article-title":"Patient-reported outcomes after low-dose-rate versus high-dose-rate brachytherapy boost in combination with external beam radiation for intermediate and high risk prostate cancer","volume":"20","author":"Dhere","year":"2021","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2024.12.005_bib0022","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.brachy.2022.04.006","article-title":"Combined brachytherapy and ultra-hypofractionated radiotherapy for intermediate-risk prostate cancer: comparison of toxicity outcomes using a high-dose-rate (HDR) versus low-dose-rate (LDR) brachytherapy boost","volume":"21","author":"Kollmeier","year":"2022","journal-title":"Brachytherapy"},{"issue":"1","key":"10.1016\/j.brachy.2024.12.005_bib0023","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ijrobp.2024.02.064","article-title":"A randomized trial comparing quality of life after LDR or HDR prostate brachytherapy boost with pelvic external beam radiation therapy","volume":"120","author":"Crook","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2024.12.005_bib0024","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.radonc.2020.04.038","article-title":"A biochemical definition of cure after brachytherapy for prostate cancer","volume":"149","author":"Crook","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2024.12.005_bib0025","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.brachy.2013.08.004","article-title":"Validation study of ultrasound-based high-dose-rate prostate brachytherapy planning compared with CT-based planning","volume":"13","author":"Batchelar","year":"2014","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2024.12.005_bib0026","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.brachy.2014.05.006","article-title":"Ultrasound-planned high-dose-rate prostate brachytherapy: dose painting to the dominant intraprostatic lesion","volume":"13","author":"Crook","year":"2014","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2024.12.005_bib0027","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/cncr.23139","article-title":"The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer","volume":"112","author":"Abramowitz","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.brachy.2024.12.005_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2022.109460","article-title":"Outcomes following brachytherapy boost for intermediate- and high-risk prostate cancer: a retrospective bicenter study by the SFRO brachytherapy group","volume":"180","author":"Ka","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2024.12.005_bib0029","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.radonc.2017.06.012","article-title":"High-dose-rate brachytherapy boost for prostate cancer treatment: different combinations of hypofractionated regimens and clinical outcomes","volume":"124","author":"Vigneault","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2024.12.005_bib0030","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/bju.13659","article-title":"Long-term outcomes of high-dose-rate brachytherapy for intermediate- and high-risk prostate cancer with a median follow-up of 10 years","volume":"120","author":"Yaxley","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.brachy.2024.12.005_bib0031","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1200\/JCO.19.03217","article-title":"Addition of androgen-deprivation therapy or brachytherapy boost to external beam radiotherapy for localized prostate cancer: a network meta-analysis of randomized trials","volume":"38","author":"Jackson","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.brachy.2024.12.005_bib0032","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.brachy.2016.11.017","article-title":"American Brachytherapy Society task group report: use of androgen deprivation therapy with prostate brachytherapy\u2014a systematic literature review","volume":"16","author":"Keyes","year":"2017","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2024.12.005_bib0033","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.radonc.2020.06.039","article-title":"Does ADT benefit unfavourable intermediate risk prostate cancer patients treated with brachytherapy boost and external beam radiotherapy? A propensity-score matched analysis","volume":"150","author":"Mendez","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2024.12.005_bib0034","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.eururo.2023.03.001","volume":"84","author":"Chow","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.brachy.2024.12.005_bib0035","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ijrobp.2019.11.415","article-title":"Radiation dose escalation or longer androgen suppression to prevent distant progression in men with locally advanced prostate cancer: 10-year data from the TROG 03.04 RADAR trial","volume":"106","author":"Joseph","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2024.12.005_bib0036","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.radonc.2011.08.022","article-title":"Is single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer?","volume":"100","author":"Morton","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2024.12.005_bib0037","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.urology.2016.01.012","article-title":"Decipher genomic classifier measured on prostate biopsy predicts metastasis risk","volume":"90","author":"Klein","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.brachy.2024.12.005_bib0038","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.brachy.2015.12.008","article-title":"Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: comparison of two consecutive high-dose-rate schemes","volume":"15","author":"Olarte","year":"2016","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2024.12.005_bib0039","first-page":"1","article-title":"A comparison of outcomes for patients with intermediate and high risk prostate cancer treated with low dose rate and high dose rate brachytherapy in combination with external beam radiotherapy","volume":"20","author":"Slevin","year":"2019","journal-title":"Clin Transl Radiat Oncol"}],"container-title":["Brachytherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472125000042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472125000042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T12:38:33Z","timestamp":1740746313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538472125000042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1538472125000042"],"URL":"https:\/\/doi.org\/10.1016\/j.brachy.2024.12.005","relation":{},"ISSN":["1538-4721"],"issn-type":[{"value":"1538-4721","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HDR brachytherapy combined with external beam radiotherapy for unfavorable localized prostate cancer: A single center experience from inception to standard of care","name":"articletitle","label":"Article Title"},{"value":"Brachytherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brachy.2024.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of American Brachytherapy Society.","name":"copyright","label":"Copyright"}]}}